NCT00905424: Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant |
|
|
| Completed | 2 | 246 | US | Antidepressant + SPD489 (lisdexamfetamine dimesylate), LDX, Vyvanse, Antidepressant + placebo | Shire | Major Depressive Disorder | 08/10 | 08/10 | | |
NCT00985725: SPD489 in Adults With Persistent Executive Function Impairments (EFI) and Partial or Full Remission of Recurrent Major Depressive Disorder |
|
|
| Completed | 2 | 143 | US | SPD489 (Lisdexamfetamine dimesylate), Vyvanse, Matching placebo | Shire | Major Depressive Disorder | 04/11 | 04/11 | | |
| Completed | 2 | 1197 | Europe, US, RoW | Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Vyvanse, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg, Antidepressant + Placebo | Shire | Major Depressive Disorder | 01/14 | 01/14 | | |
